Tuesday 20 February 2018
Contact US    |    Archive
Reuters
5 months ago

BRIEF-Interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.
Hashtags:   

BRIEF

 | 

Interim

 | 

analysis

 | 

from

 | 

phase

 | 

open

 | 

label

 | 

extension

 | 

study

 | 

Soliris

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
USA